Dr. Colón brings over 25 years experience in biopharma, genomics, healthcare, drug delivery and industrial biotechnology. Currently she is President and CEO at InCarda Therapeutics, a biopharmaceutical company pioneering a novel approach of treating cardiovascular conditions and diseases by the inhalation route. She is also a senior advisor at New Science Ventures (where she was formerly a partner), serves on the boards of Proterix Bio (Executive Chairman; formerly CEO) and PerceptiMed, and is an advisor at Kiverdi. She has served as a member of the Advisory Board of the Miller Center for Social Entrepreneurship at Santa Clara University since 2014. She also co-founded Pyranose Biotherapeutics, an early stage discovery platform company. Previously she was founding President of the Industrial Products Division at Intrexon Corporation, where she established a new division focused on leveraging synthetic biology for bioindustrial applications such as biofuels and renewable chemicals and was a key contributor to the company’s $100M Series E raise. Prior to Intrexon, she was head of Clinical Operations for Gilead Sciences, where she was responsible for global execution of clinical trials. At Gilead, she also created and led both the Alliance Management and Commercial Strategic Planning groups. Prior to Gilead, she was VP, Corporate Planning at Affymetrix, where she was responsible for strategic planning and project management and where she also served as COO for the International Genomics Consortium, a non-profit medical research organization focused on cancer genomics. Earlier in her career she was a consultant with McKinsey & Co., where she served clients in healthcare, biotech, high tech and venture capital. She was also an engineer with Merck & Co. in France and in Rahway, NJ. Dr. Colón received her Ph.D. in chemical engineering from the Massachusetts Institute of Technology and holds a B.S. degree in chemical engineering from the University of Pennsylvania, where she was a Benjamin Franklin Scholar.